Moderna’s Shift to Cancer Company Lifts Stock Up 177%

The New York Times – Business:

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

Author: RSS Feed

This post first appeared in The New York Times – Business. Read the original article.